Literature DB >> 1979878

Effect of melanotropin release inhibiting factor on changes by haloperidol and centbutindole in cerebral cortical 5-hydroxytryptamine receptors.

A Gulati1, H N Bhargava.   

Abstract

The effect of melanotropin release inhibiting factor (Pro-Leu-Gly-NH2, MIF) was determined on changes induced by two neuroleptics, haloperidol and centbutindole, in cerebral cortical 5-hydroxytryptamine (5-HT) receptors. Male Sprague-Dawley rats were injected daily i.p. with vehicle, haloperidol (1.0 mg/kg) or centbutindole (0.5 mg/kg), respectively, for 21 days. On day 22, these 3 groups were further divided into 2 subgroups and injected with either vehicle or MIF (2.0 mg/kg, i.p.) daily for 3 days. 3H-5-HT was used to study 5-HT1 receptors, and 3H-spiroperidol to label 5-HT2 receptors in the cerebral cortex. Chronic administration of haloperidol significantly increased (39.7%) the maximal binding capacity (Bmax) of 3H-5-HT binding to 5-HT1 receptors. Dissociation constant (Kd) values did not change. Centbutindole had no effect on 5-HT1 receptors. MIF had no effect on 5-HT1 receptors, nor did it alter haloperidol-induced increases in the Bmax of 3H-5-HT binding to 5-HT1 receptors. Chronic administration of centbutindole significantly increased (61.1%) the Bmax of 3H-spiroperidol binding to 5-HT2 receptors. No change occurred in the Kd values. Chronic treatment with haloperidol had no effect on 5-HT2 receptor characteristics. MIF had no effect on 5-HT2 receptors or on the increase in 5-HT2 receptor density induced by centbutindole. The behavioral syndrome induced by 5-hydroxytryptophan (5-HTP) (50, 100 and 200 mg/kg, i.p.) was also measured in rats treated chronically with haloperidol or centbutindole. Haloperidol had no effect on the 5-HTP syndrome, whereas centbutindole stimulated by 24-45% the intensity of the syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979878     DOI: 10.1159/000138704

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Comparative efficacy of centbutindole & risperidone in schizophrenia.

Authors:  R Chandra; H Singh; P K Dalal; O P Asthana; J S Srivastava
Journal:  Indian J Psychiatry       Date:  2002-10       Impact factor: 1.759

2.  A comparative efficacy study of centbutindole and haloperidol in schizophrenia.

Authors:  H Singh; J S Srivastava; C Raghuvanshi; P K Dalal; O P Asthana
Journal:  Indian J Psychiatry       Date:  1999-10       Impact factor: 1.759

3.  Allosteric modulation of the dopamine receptor by conformationally constrained type VI beta-turn peptidomimetics of Pro-Leu-Gly-NH2.

Authors:  Ashish P Vartak; Kevin Skoblenick; Nancy Thomas; Ram K Mishra; Rodney L Johnson
Journal:  J Med Chem       Date:  2007-12-01       Impact factor: 7.446

4.  Brain Activation by Peptide Pro-Leu-Gly-NH(2) (MIF-1).

Authors:  Reas S Khan; Chuanhui Yu; Abba J Kastin; Yi He; Rudolph H Ehrensing; Hung Hsuchou; Kirsten Prufer Stone; Weihong Pan
Journal:  Int J Pept       Date:  2010-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.